Brazil ANVISA Regulatory Reliance: June 2024 Update to IN 290/2024 Streamlines Class III/IV Device Review

Brazil ANVISA Regulatory Reliance: June 2024 Update to IN 290/2024 Streamlines Class III/IV Device Review

Brazil's ANVISA has updated its review process for the regulatory reliance pathway under IN 290/2024. As of mid-June 2024, instead of rejecting submissions with minor issues, the agency will now issue requirement notices, allowing manufacturers to amend their applications. This episode explains how this change de-risks the submission process for Class III and IV medical devices that rely on approvals from Australia, Canada, the U.S., or Japan, making the pathway more efficient and predictable. Key Questions: - What is Brazil's new regulatory reliance pathway under IN 290/2024? - How has ANVISA's review process for reliance submissions changed as of June 2024? - Why is this change significant for manufacturers of Class III and IV medical devices? - What were the risks of the reliance pathway before this update? - How does the new process of issuing requirement notices reduce submission risk? - Which foreign regulatory approvals are recognized by ANVISA for this pathway? - What practical steps should your regulatory team take to prepare a successful reliance submission? - How can you ensure your submission avoids triggering a requirement notice from ANVISA? Sources: - https://www.emergobyul.com/news/regulatory-reliance-authorizations-brazils-revised-anvisa-process-june-2026 - https://www.emergobyul.com/news/anvisa-updates-hospitalar-2026-attendees-about-regulatory-reliance How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, simplifying access to over 30 global markets, including Brazil. Our experts can help you develop an efficient regulatory strategy for the ANVISA reliance pathway, manage the technical dossier preparation, and act as your local representative to handle all communications with the agency, including responding to requirement notices. We combine local expertise with advanced AI to accelerate your submission and ensure compliance. For help with your market access strategy, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

China NMPA Post-Market Vigilance 2026: New Rules for Foreign Manufacturers

This episode provides a detailed analysis of China's NMPA new post-market vigilance framework, released on June 12, 2026. We discuss the mandatory, risk-based system that introduces new obligations for foreign medical device manufacturers, including detailed requirements for trend reporting, Periodic Safety Update Reports (PSURs), and comprehensive vigilance planning. Learn about the immediate compliance steps your company must take to maintain market access in China. Key Questions: - What are the key components of China's new post-market vigilance framework? - How does the NMPA's 2026 update affect overseas medical device manufacturers? - What are the new requirements for Periodic Safety Update Reports (PSURs) in China? - What is trend reporting and how must it be implemented under the new NMPA rules? - What specific actions should regulatory teams take to ensure compliance with these changes? - How does the risk-based approach change post-market surveillance obligations in China? - What is the role of the China Agent in this new vigilance system? - Are there immediate deadlines for implementing these new vigilance plans? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGLsm9oWY0mwgxGjOzXpOhnX6mb_eSYMd2eJdGyRW0KTBfhCtttdPOeRD_8Nzyq12FBpBPa4wS6BUSh2s2v_RM1MEMGAW5cSZriDznF0Hal8q-yufaFLrzpxl-HiaKZ7gNmqblkfoIwzbba8Mf0L816TbpmNJLGIJzzqf6rbXvJCSw= How Pure Global can help: Navigating China's complex regulatory landscape requires local expertise and a proactive strategy. Pure Global provides end-to-end support for MedTech and IVD companies, from initial registration to post-market surveillance and vigilance compliance. Our in-country experts in China can act as your legal agent, help you develop an NMPA-compliant vigilance plan, and manage your reporting obligations. We leverage advanced AI tools to streamline dossier preparation and monitor regulatory changes, ensuring you maintain compliance and market access. Visit https://pureglobal.com or contact us at info@pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.

Saudi SFDA's 2026 AI Medical App Approval: A Global First for Vital Signs Monitoring

On June 22, 2026, the Saudi Food and Drug Authority (SFDA) issued a landmark marketing authorization for an AI-powered mobile application that measures vital signs using a smartphone camera. We break down the technology behind this global first, remote photoplethysmography (rPPG), and explore the innovative regulatory pathways the SFDA used, including its Regulatory Sandbox. This episode details the significant implications for AI and SaMD manufacturers, highlighting why Saudi Arabia is emerging as a key market for digital health innovation and what this means for market access strategies in the MENA region. Key Questions: - What is the significance of the SFDA's June 2026 approval for an AI-powered medical app? - How does remote photoplethysmography (rPPG) technology measure vital signs using a smartphone? - What are the SFDA's Regulatory Sandbox and Innovative Medical Devices pathways? - Why is Saudi Arabia becoming a key market for digital health and SaMD manufacturers? - What does this approval mean for companies targeting the MENA region? - What practical steps should regulatory teams take in response to this development? - How does this event align with Saudi Arabia's Vision 2030 healthcare goals? - What kind of precedent does this set for global AI medical device regulation? Sources: - https://www.einpresswire.com/article/722233834/sfda-grants-marketing-authorization-for-ai-powered-medical-app-to-measure-vital-signs - https://saudigazette.com.sa/article/643877/SAUDI-ARABIA/SFDA-grants-marketing-authorization-for-AI-powered-medical-app-to-measure-vital-signs - https://www.arabnews.com/node/2535536/saudi-arabia How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to enter or expand in over 30 global markets, including Saudi Arabia. We combine local expertise with advanced AI to develop efficient market access strategies, manage technical dossier submissions, and act as your in-country representative. Our team can help you navigate novel pathways like the SFDA's Regulatory Sandbox to accelerate your product's journey to market. For support with your global regulatory needs, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

UK MHRA MDSAP Membership: Streamlining Audits for UK, US, Canada, and More

The UK's MHRA announced on June 22, 2026, its intention to become a full member of the Medical Device Single Audit Program (MDSAP). This episode explores the significant impact of this decision on medical device manufacturers. We discuss how full membership will streamline the audit process, allowing a single quality management system audit to satisfy requirements for the UK, US, Canada, Australia, Brazil, and Japan. We also cover the strategic implications for the UK's post-Brexit regulatory framework and provide practical steps for regulatory and quality teams to prepare for this change. Key Questions: - What is the Medical Device Single Audit Program (MDSAP)? - What did the UK MHRA announce on June 22, 2026, regarding its MDSAP status? - How does full MDSAP membership differ from the UK's current affiliate status? - Which countries' regulatory requirements can be met with a single MDSAP audit? - How will this change reduce the audit burden for medical device manufacturers? - What does this move signal about the UK's post-Brexit regulatory strategy? - What practical steps should regulatory teams take to prepare for this transition? - Could this development make the UK a more attractive market for device companies? Sources: - https://medtech.pharmaintelligence.informa.com/MT148334/MDSAP-Move-Underlines-MHRAs-Global-Device-Regulatory-Ambitions How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex global markets. Whether you're dealing with changes like the UK's integration into MDSAP or planning a multi-market launch, our team of local experts and advanced AI tools can create an efficient regulatory strategy. We act as your local representative and manage technical dossier submissions to get your products approved faster. To learn how we can streamline your market access, visit us at https://pureglobal.com, email info@pureglobal.com, or explore our free AI regulatory tools and global device database at https://pureglobal.ai.

Singapore HSA COVID-19 IVD Reclassification: Class C Requirements from 2026

Singapore's Health Sciences Authority (HSA) is reclassifying all COVID-19 in-vitro diagnostic (IVD) tests from the highest-risk Class D to Class C, effective June 2, 2026. This episode details the reasons for this regulatory shift as COVID-19 becomes endemic, explains the differences between Class C and Class D requirements, and outlines the practical impact on technical documentation, quality management systems, and post-market surveillance for IVD manufacturers marketing products in Singapore. Key Questions: - What is the new risk classification for COVID-19 IVD tests in Singapore? - Why did Singapore's Health Sciences Authority (HSA) make this change? - When does this new classification officially take effect? - How does the Class C regulatory pathway differ from the Class D pathway for IVDs? - What are the specific changes to technical documentation and submission requirements? - Will existing COVID-19 IVDs need to be re-registered under the new class? - How does this reclassification impact post-market surveillance obligations? - What immediate actions should regulatory teams take to prepare for this transition? Sources: - https://www.morulaa.com/singapore-hsa-announces-regulatory-updates-for-medical-devices-ivds/ - https://www.hsa.gov.sg/medical-devices/guidance-documents How Pure Global can help: Navigating regulatory changes like Singapore's IVD reclassification requires local expertise and a clear strategy. Pure Global provides comprehensive support for MedTech and IVD companies, acting as your local Singapore Registrant and managing the entire registration process. Our team of experts and advanced AI tools can help you efficiently update your technical dossiers, adapt your quality management system, and ensure a seamless transition to the new Class C requirements. To learn how we can accelerate your market access in over 30 countries, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free regulatory AI tools and device database at https://pureglobal.ai.